Liquidia Technologies to Report 2018 Financial Results and Provide Corporate Update on February 26, 2019
RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2019 (GLOBE NEWSWIRE) -- , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its to transform the lives of patients, today announced that 2018 financial results will be reported on Tuesday, February 26, 2019. The company will host a webcast and conference call at 8:00 a.m. ET to discuss financial results and provide a corporate update.
The live call may be accessed by dialing 1-877-707-8711 (domestic) and 1-857-270-6219 (international), and entering the conference code: 5960248. A live and archived webcast of the call will be available on the page of Liquidia’s website.
About Liquidia Technologies
is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT® particle engineering platform: for the treatment of pulmonary arterial hypertension and for the treatment of local post-operative pain. Being evaluated in a Phase 3 clinical trial (INSPIRE), LIQ861 is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, palm-sized, disposable dry powder inhaler. LIQ865, for which Liquidia has completed two Phase 1 clinical trials, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. For more information visit our website at .
Contact Information
Investors:
Jenny Kobin
IR Advisory Solutions
919.328.4389
Media:
Christy Curran
Sam Brown Inc.
615.414.8668
